周圣斌
个人信息
职称 副研究员
学历 博士
电话 0571-86080393
邮箱 szz59@ucas.ac.cn
通讯地址 浙江省杭州市西湖区象山支弄1号1号楼3B-305
2010.9-2015.7 中国科学院上海药物研究所,药物化学,博士,导师:柳红研究员
2006.9-2010.7 中国药科大学,制药工程,工学士
工作经历
2020.12至今国科大杭州高等研究院,药物科学与技术学院,副研究员
2016.6-2020.9美国宾夕法尼亚州立大学,化学系和生物化学及分子生物学系,博士后,
合作导师:J. Martin Bollinger, Jr.和Carsten Krebs
2015.7-2016.5中国科学院上海药物研究所,柳红组,助理研究员
1.天然产物药物及其衍生物的结构修饰及构效关系研究
2.天然产物生物合成路径中关键酶的作用机制研究,新功能表征及进化改造
3.活性天然产物潜在的作用机制研究
1. EV71 3C蛋白酶抑制剂的设计、合成及抗病毒活性研究,国自然青基(21602234),主持,
2.糖抑制剂合成技术服务,科研协作(2021HX01B05002),主持
3.糖类药物研发关键技术与品种,杭州市领军型创新创业团队项目(TD2020005),主持
代表论著
1.Copeland, R.*,Zhou, S., Schaperdoth, I., Shoda, T. K., Bollinger, M.*, Krebs, C.*; Hybrid radical-polar pathway for excision of ethylene from 2-oxoglutarate by an iron oxygenase,Science, 2021,373, 6562, 1489-1493.
2.Zhou, S.,*Pan, J., Davis, K., Schaperdoth, I., Wang, B., Boal, A., Krebs, C.,*Bollinger, J. M., Jr.*Steric Enforcement ofcis-Epoxide Formation in the Radical C–O-Coupling Reaction by Which (S)-2-Hydroxypropylphosphonate Epoxidase (HppE) Produces Fosfomycin.J. Am. Chem. Soc.2019,141, 51, 20397-20406.JACS Spotlight.J. Am. Chem. Soc.2020,142, 6, 2697-2698.
3.Zhou, S.; Wang, S.; Wang, J.; Nian, Y.; Peng, P.; Soloshonok, V. A.; Liu, H., Configurationally Stable (S)- and (R)-α-Methylproline-Derived Ligands for the Direct Chemical Resolution of Free Unprotected β3-Amino Acids.Eur. J. Org. Chem.2018,15, 1821-1832.
4.Zhou, S.,†Duan, Y.N.,†Wang, J.,†Zhang J., Sun, H., Jiang H, Gu Z, Tong J, Li J, Li, J., Liu, H. Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.Eur. J. Med. Chem.2017,10, 448-464.
5.Zhou, S., Wang, J., Chen, X., Aceña, J., Soloshonok, V. A.,*Liu, H.*Chemical kinetic resolution of unprotected β-substituted-β-amino acids using recyclable chiral ligands.Angew. Chem. Int. Ed.2014,53, 7883-7886.
6.Zhou, S., Wang, J., Lin, D., Zhao, F., Liu, H. Enantioselective synthesis of 2-substitued-tetrahydroisoquinolin-1-yl glycine derivatives via oxidative cross-dehydrogenative coupling of tertiary amines and chiral nickel(II) glycinate.J. Org. Chem.2013,78, 11204-11212.
7.Zhou, S., Wang J., Liu, H. Lead compound optimization strategy (5) – reducing hERG cardiac toxicity in drug development. (Chinese Review).Acta Pharm. Sin., 2016,51, 1530-1539.
8.Li, T.,†Zhou, S.,†Wang, J., Acena, J. L., Soloshonok, V. A., Liu, H.Asymmetric Synthesis of (2S,3S)‑α-(1-Oxoisoindolin-3-yl)glycines under Low-Basicity “Kinetic” Control.J. Org. Chem.2015,80, 11275-11280.